Qube Research & Technologies (QRT)’s C4 Therapeutics CCCC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.98M	Buy	2,397,086 +2,026,532	+547%	+$7.56M	0.01%	1577
2026 Q2	$1.73M	Sell	370,554 -381,560	-51%	-$1.31M	﹤0.01%	2189
2026 Q1	$1.98M	Buy	752,114 +461,880	+159%	+$1.09M	﹤0.01%	2184
2025 Q4	$554K	Buy	290,234 +174,261	+150%	+$413K	﹤0.01%	2770
2025 Q3	$257K	Buy	+115,973	New	+$278K	﹤0.01%	2887
2024 Q3	–	Sell	-258,426	Closed	-$1.19M	–	3384
2024 Q2	$1.19M	Sell	258,426 -129,767	-33%	-$774K	﹤0.01%	1813
2024 Q1	$3.17M	Buy	388,193 +361,103	+1,333%	+$2.8M	0.01%	1486
2023 Q4	$153K	Buy	27,090 +20,204	+293%	+$46.1K	﹤0.01%	2935
2023 Q3	$12.8K	Sell	6,886 -69,896	-91%	-$213K	﹤0.01%	3271
2023 Q2	$211K	Buy	76,782 +47,094	+159%	+$151K	﹤0.01%	1761
2023 Q1	$93.2K	Buy	+29,688	New	+$175K	﹤0.01%	2138

Other funds holding CCCC

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CCCC Position: Q3 2026 in Review

Qube Research & Technologies (QRT) increased its C4 Therapeutics (CCCC) stake by 547% in Q3 2026, buying an estimated $7.56M and bringing the position to 2,397,086 shares worth $7.98M. The position accounts for 0.01% of the portfolio, ranked #1577.

Qube Research & Technologies (QRT) first reported a position in CCCC in Q1 2023 and has held it in 11 quarters since. 80 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

Qube Research & Technologies (QRT) held 2,397,086 shares of C4 Therapeutics worth $7.98M as of Q3 2026.
Qube Research & Technologies (QRT) bought 2,026,532 C4 Therapeutics shares in Q3 2026, an estimated $7.56M.
C4 Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #1577 holding.
Qube Research & Technologies (QRT) first reported a position in C4 Therapeutics in Q1 2023 and has held it in 11 quarters since.
80 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.